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Abstract
While one of the major clinical and scientific challenges in the management of implant-related infections and post-
operative complications after surgery is the application of new techniques, a new approach is pertinent in the design 
of medical implants to reduce bacterial infections. We have designed and tested antibiotic-containing biocomposite 
thin films of polylactic acid (PLA), and coralline-derived hydroxyapatite (HAp) as controlled drug delivery systems for 
the treatment of dental, orthopaedic and neural implant-related post-operative infections. These films can be applied to 
complicated designs of dental, miniaturized neural devices, cochlear or total hip replacement (THR) implants by spray or 
dip-coating techniques. Current results reveal that the devices could release antibiotic in a controlled manner to prevent 
significantly bacterial growth and biofilm production. Hydroxyapatite within the composites controls the release rate 
and also supplies minerals, such as calcium  Ca2+ and phosphate  PO4
2− ions, which are essential minerals for bone tissue
regeneration. It is concluded from the physical, mechanical and biological properties that these coatings and devices 
could easily be utilized in a wide range of biomedical applications.
Keywords Implant coating · Dental implant · Drug release · Antibiotic · Hydroxyapatite · Polymer composite · Biofilm · 
Post-operative infection · Cochlear devices · Neural devices
1 Introduction
Controlled slow drug delivery systems and devices have 
been developed in human health-care areas in order to 
solve, among many, post-operative complications such 
as implant-related infections. Although numbers of new 
novel drug therapies have been developed, the main 
problem has been to keep the ideal concentration of drug 
constantly and steady during long-term delivery, which 
may cause medical problems. Indeed, this kind of long-
term systemic drug therapies might result in toxicity in 
certain internal organs, such as kidneys.
In order to control drug release rate into the desired 
part of the human body, controlled drug delivery tech-
niques have been used with the application of various bio-
composite devices and materials, which may contain natu-
ral or synthetic biodegradable polymers or bioceramics as 
the matrix. In addition, a number of different drug carriers 
have been introduced, such as polysaccharides and cal-
cium phosphates containing different pharmaceuticals for 
different treatments according to the design of the drug 
delivery system. It has been reported that this kind of con-
trolled release systems provides efficacy, reduces toxicity 
and also improves early patient recovery [1, 2].
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A wide range of materials from natural materials to 
polymers and ceramics has been successfully used as a 
drug carrier for the delivery of different clinical active 
agents. However, marine shells and skeletons as calcium 
carbonate or calcium phosphates show a better promise 
due to their excellent biocompatibility and their unique 
architecture of interconnected pores, which allow load-
ing of drugs and slow release. As stated earlier, these cal-
cium carbonate structures can easily be fully converted 
into resorbable calcium phosphates with controllable 
dissolution rates [3–6]. The uniform interconnected 
porosity in these marine materials together with their 
controllable dissolution rate makes a complementary 
potential for tunable drug loading and release rates and 
the improvement of drug bioavailability and efficacy.
Biodegradable polymers have been widely used in 
medical technology [7]. Polylactic acid (PLA), polygly-
colide (PGA) and their copolymers are acid anhydrides and 
among the widely used biodegradable synthetic polymers. 
They have demonstrated to be excellent biodegradable 
materials with non-toxic degradable products [8]. In addi-
tion, Lou and his colleagues [9] showed that the proper-
ties of synthetic aliphatic biopolymers could be tuned for 
specific applications. While PLA has been used in a number 
of clinical applications, such as sutures, stents, and dialysis 
media, it is also highly useful for controlled drug delivery 
systems in form of a matrix, because of its bio-degradation 
kinetics and mechanical properties [2, 10, 11].
We have previously reported that the combination 
of marine bioceramics and an appropriate biodegrad-
able polymer can form a biocomposites that have added 
advantages in slow drug delivery systems specifically the 
controlled delivery rates and the additional mineral deliv-
ery that can help both hard and soft tissue growth. It is also 
reported that these biocomposites display improved prop-
erties of strength and toughness [12]. Polymer-bioceramic 
thin-film biocomposites are flexible enough to conform to 
any shape and size and could be used as implant coatings, 
especially in dental and orthopaedic areas, and new neural 
devices and sensors. The most of the current orthopaedic 
implantable devices are produced by metallic substrates, 
such as Ti and CoCrMo alloys. Although metallic implants 
have the appropriate mechanical properties and relatively 
good corrosion resistance, they can cause metal-allergic 
reactions in certain patients and possible infection after 
surgery. Therefore, various types of surface modifications 
on the metallic implants have been designed and devel-
oped in order to eliminate these uncertainties [13, 14].
For this reason, antibiotic-containing PLA/hydroxyapa-
tite ceramic thin-film biocomposites as coating materials 
have been developed in order to improve the surface 
properties of the implants, to prevent implant-related 
infections, and also to provide treatments for various post-
operation complications, such as osteomyelitis [15].
The development of bone tissue engineering in the 
past has been related directly to modifications in the 
types of materials used. The repair process is somewhat 
compromised in numerous pathological and clinical situ-
ations despite bone’s capability for regenerative growth. 
At present, a number of synthetic bone graft biomaterials, 
such as calcium phosphate, are available as options to an 
autogenous bone for augmentation, repair or substitution. 
New advancements associated with calcium phosphate 
scaffolds, such as improvements in microstructure and sur-
face properties, have created new opportunities for bone 
regenerative technologies. These recent developments 
also make the calcium phosphate scaffolds to be thought 
of as biologically instructive instead of being osteocon-
ductive scaffolds. Evidence has also suggested that certain 
engineering bioceramics, such as calcium phosphate, have 
a direct influence on the proliferation and differentiation 
of human mesenchymal stem cells in addition to being 
osteoinductive. Tissue engineering along with new bioac-
tive molecules enhanced the possible applications of cal-
cium phosphate as scaffolds are able to guide the behav-
iour of these cells and the efficiency of bone regeneration 
as well as being carriers of these cells.
It is widely accepted in the medical community that 
wound contamination as well as post-operative infec-
tions following implantation or during surgical interven-
tion in orthopaedics and maxillofacial surgery can result 
in serious clinical problems and could jeopardize the osse-
ointegration process. For these reasons antibiotics either 
administered orally or intravenously are often provided 
as prophylactics. By far the most frequent complications 
related to the use of implantable medical devices, such 
as orthopaedic or dental prostheses and endotracheal 
tubes, are bacterial infections. Pseudomonas aeruginosa is 
considered to be responsible for internal device-related 
infections leading to morbidity and mortality. Staphylo-
coccus aureus, on the other hand, cause serious infections 
relating to severe sepsis and deep-seated infection and 
septic-thrombosis infections. S. aureus and Staphylococcus 
epidermidis strains, including methicillin-resistant S. aureus 
(MRSA), are the main cause of biofilm formation on the 
medical devices which requires surgical intervention for 
the treatment. Fighting biofilm formation requires deep 
and comprehensive understanding of the molecular bases 
of its formation. Osteoarticular infection is frequently 
caused by coagulase-negative Staphylococci as main 
aetiologic agents in late infections as well as Streptococci, 
Enterococci and anaerobes. The number of infections has 
been estimated to be around 0.5–2.0% of all cases, and 
it increases continuously due to the rise in the need for 
implants.
The European Center for Disease Prevention and Con-
trol (ECDPAC) reported that approximately 4100,000 
patients are estimated to acquire infections in the Euro-
pean Union every year. It has been estimated that at least 
37,000 direct deaths occur as the result of these infec-
tion and it contributes to an additional 110,000 deaths 
each year. Furthermore, it has been estimated that 5% of 
patients undergoing surgical procedures and up to 20% 
of patients having intra-abdominal surgical procedures 
develop a surgical site infection which result in exces-
sive hospital days and more than US$1.6 billion hospital 
costs per year. Number of mitigations has been suggested 
including preventing and/or controlling bacterial infec-
tions. Specifically, modification or development of thin 
and flexible films or nanocoated multilayer devices with 
surface properties that have an effect on microbial adhe-
sion or viability seems to be a promising approach for the 
prevention of device-related infections. On the other end, 
the possibility to modify the surface of medical devices 
biologically, chemically or physically to render the surface 
free of microbial adhesion is suggested to be alternative 
strategies as well. Multifunctional thin biocomposite films 
or nanocoatings can facilitate this new approach. As stated 
earlier for orthopaedic-dental and tissue regeneration, 
polymer-bioceramic biocomposites have advantages of 
improved bioactivity, drug encapsulation efficiency and 
stability as well as delivery of essential mineral ions of cal-
cium and phosphate for bone regeneration and repair. In 
neural sensors, they show improved biocompatibility and 
allow the delivery of different drugs locally. In the past a 
number of drug delivery techniques for the effective treat-
ment of neurological disorders, such as direct injection, 
ultrasound [16], pharmacological and physiological (non-
invasive) [17], neurosurgical strategies and intracerebral 
implants have not been proved to be fully effective or ideal 
[18].
A report from the World Health Organization (WHO) 
shows that diseases related to the central nervous system 
affect nearly a billion people globally, causing immense 
clinical and economic burden [19]. The reports also 
showed that nearly 17% of the world’s population suffers 
from different neurological disorders such as neuro-infec-
tions, multiple sclerosis, Parkinson diseases, brain injuries 
and strokes. There are over 600 neurological disorders, 
each presenting with different symptoms and affecting 
different parts of the central nervous system (CNS). There 
have been tremendous efforts towards improving diag-
nostic procedures and development of improved thera-
pies for CNS. Effective and low-cost treatment for most of 
the CNS diseases is available; nevertheless, the treatment 
is limited by the blood–brain barrier (BBB) which hinders 
adequate penetration of therapeutic agents [20]. One of 
the main functions of BBB is to provide physical protection 
to the brain from getting infections; on the other hand, it 
acts as a physical barrier inhibiting the passage of active 
clinical agents to the CNS. Traditional administrations of 
drugs, such as oral or intravenous, are normally given in 
large doses to ensure some drug reaches the brain. Since 
this is not really targeted, it potentially poses unwanted 
side effects, especially in young children. The size and the 
type of the local delivery system are important. Nanopar-
ticles have been designed to deliver therapeutic agents 
for the treatment of Alzheimer’s disease. The particles 
could release the drug in a controlled manner for up to 
few days to weeks [21, 22]. One of the drawbacks of nano-
carriers is that they cannot uptake enough amount of drug 
to sustain a prolonged period of drug release. However, 
the use of biocompatible nanoparticles could increase 
the chance of improving the penetration of active clini-
cal agents through BBB [23]. With the available technol-
ogy and research efforts, proper design using appropriate 
materials could improve the delivery of drugs over a pro-
longed period of time. Moreover, an in-depth understand-
ing of nanoparticles and their possible side effects are to 
be explored for their full potentials.
Once the above-mentioned new-generation biocom-
posite thin films are applied to appropriate miniaturised 
sensors and devices; it is envisaged that the drugs can 
become slowly active clinical agents delivered to a tar-
geted area minimizing the resistance from BBB with rela-
tively smaller doses and lesser side effects compared to 
oral administration or systemic delivery of medication. 
The biocomposites consisting of hydroxyapatite derived 
from marine structures are developed and character-
ized as antibiotic delivery devices with the possible use 
in the treatment of dental, orthopaedic and CNS-related 
diseases and neural prostheses-related infections. These 
implant-related infections can be prevented by the use of 
targeted antibiotics, and this paper provides the research 
conducted by using this novel drug delivery system which 
consists of antibiotic-containing calcium phosphate micro-
spheres and biodegradable polylactic acid (PLA) polymer 
biocomposite.
2  Materials and methods
2.1  Materials
Coralline materials were obtained from Queensland Aus-
tralia. Gentamicin (antibiotic), sodium hypochlorite and 
diammonium hydrogen phosphate ((NH4)2HPO4, 98%) 
were purchased from Sigma-Aldrich, Castle Hill, Australia. 
High-purity Ti–Al–V discs were obtained from the Good 
Fellows UK. Bacteria Staphylococcus aureus (SH1000) for 
minimum inhibition concentration study, derived from 
sepsis isolate (NCTC 8325), Staphylococcus aureus (ATC 
25,923) and Pseudomonas aeruginosa (ATCC 15692) for 
biofilm studies were supplied by Sigma-Aldrich, Australia.
2.2  Methods
2.2.1  Hydroxyapatite from coralline materials
According to the methods described in Ben-Nissan et al. 
[24, 25], coralline powder samples were converted into 
hydroxyapatite by a hydrothermal method in a Parr reac-
tor for three hours. Initially, coralline materials had to be 
cleaned with 2% (v/v) NaClO, then ball-milled to obtain a 
fine powder of approximately < 100 μm and then washed 
again and dried in an oven at 100 °C for 2 h before use.
2.2.2  Drug loading and thin‑film composites
Drug loading to hydroxyapatite particles was conducted 
in a vacuum controlled rotavapor by mixing the particles 
with drug solution to give 10% w/w loading of the drug. 
Since the HAp particle has nano- and mesopores, drug 
solution penetrates into these pores with the help of vac-
uum and also the particles are coated with a drug. After 
loading, the particles were dried in a desiccator under 
vacuum for further use. Film composites were developed 
by solution-casting method where PLA was first dissolved 
in chloroform and then mixed with particles loaded with 
drug to make PLA composites under magnetic stirrer until 
the uniform mixture followed by ultrasound and then 
casted on a Petri dish and allowed to dry under vacuum 
for three days. The following designation was assigned 
to samples as follows: PLA neat film as PLA, PLA films 
loaded with gentamicin (GM) as PLAGM, PLA composites 
with hydroxyapatite as PLAHAp, PLA composite films of 
hydroxyapatite loaded with gentamicin as PLAHApGM. 
Drug purity and drug presence in the PLA matrix were 
evaluated by Fourier transform infrared spectroscopy 
(FTIR).
2.2.3  Dip‑coating method for the implants
Dip-coating method was used in this study in order to 
apply PLA biocomposites on the Ti6Al4 V flat discs and 
screw-shaped dental implants as a coating material. Firstly, 
the substrate of a Ti6Al4 V dental implant was cleaned with 
acetone by the ultra-sonication method. The sample was 
dipped into the PLA biocomposite-chloroform solution at 
a constant speed. This method was chosen to coat metal-
lic substrates because of its easy applicability to complex 
structures.
2.2.4  Morphology of samples
The morphology of Gentamicin and HAp particles before 
and after drug loading was analysed by a scanning elec-
tron microscope (SEM) (ZEISS Supra55VP, Zeiss and 
Germany). The samples were fixed by conductive adhe-
sive tape on aluminium stubs and then coated with an 
ultrathin coating of carbon deposited on the sample by 
low-vacuum sputter coating. SEM images were carefully 
taken at various magnifications at acceleration voltages 
of 5–20 kV.
2.2.5  Fourier Transform Infrared Spectroscopy (FTIR)
The FTIR spectra of the samples were collected from 
Nicolet, Magna-IR 6700 Spectrometer FTIR (Thermo 
Fisher Scientific, Madison USA). The samples were 
ground, mixed with KBr at a ratio of 1:100 and then 
pressed into transparent pellets. Transparent pellets 
were prepared in stainless steel die by applying a uni-
axial load of 6.89 MPa pressure (Carver press). The FTIR 
spectra were collected in the range 4000–400 cm−1.
2.2.6  In vitro release experiment
The release study was conducted in a buffer solution 
(phosphate buffered saline (PBS), 0.1 M, pH 7.4) at physi-
ological temperature conditions of 37 ± 0.2 °C at 100 rpm 
in a temperature controlled water bath shaker. Samples 
with a total of 7.5 mg drug were put in a falcon tube 
with a buffer solution at a volume enough to provide 
complete dissolution of the drug from the samples, and 
the volume was maintained at all times. Experiments 
were done in triplicates. Drug concentrations in buffer 
solutions were determined by UV–vis spectrophotom-
eter (Agilent Technologies, Australia). Since Gentamicin 
does not absorb light in the visible spectrum; the sam-
ples were mixed with ortho-phataldialdehyde reagent 
prepared according to the method reported in Aviv et al. 
and Chou et al. [26, 27]. The absorbance corresponding 
to the gentamicin-reagent complex compound was then 
measured at λmax = 332 nm. The fractional release of gen-
tamicin was calculated with the help of a standard curve.
2.2.7  Preparation of media for biofilm study
Media for Pseudomonas aeruginosa (P. aeruginosa) and 
Staphylococcus aureus (S. aureus) were prepared by dis-
solving 22 g of Mueller–Hinton II BR and 30 g of Trytpic 
Soy Broth in 1 litre of MilliQ water (18 MΩ), respectively. 
Then the solutions were sterilized in an autoclave at 
121 °C and finally stored at room temperature for fur-
ther use.
2.2.8  Bacteria strains and static biofilm formation assay
Bacteria strains for biofilm study were cultured under 
aerobic and anaerobic conditions for P. aeruginosa and S. 
aureus, respectively, at 37 °C in a shaking incubator run-
ning at 250 rpm. Bacteria cells were grown overnight in 
broth media, then diluted in 1:100 and used for biofilm 
formation studies. Film composites samples were glued 
on coupons in triplicate and placed into a 12-well plate, 
then inoculated with bacteria cells suspension and sealed 
with a breathable film, and the bacteria were allowed to 
grow under static conditions at 37 °C, 5%  CO2 for 24 h and 
120 h, respectively. After the experiments, the biofilm sam-
ples were stained with green fluorescent nucleic acid stain 
and then fixed with 4% formaldehyde. The samples were 
stored in the refrigerator for image analysis.
2.2.9  Morphological study of biofilms
Images of biofilms on the surface of the film composites 
were analysed using confocal laser scanning microscopy 
(CLSM) (Nikon A1, Tokyo, Japan). A total of eight images 
per specimen were randomly taken using an oil-immersion 
lens (60 Objective lens, aperture of 1.4) in 1.0 μm slices 
with NIS Elements Confocal software.
2.2.10  Biofilm topological analysis by COMSTAT 
The images recorded by CLSM were reconstructed using 
IMARIS, and the topology of biofilms was analysed in com-
puter statistics software, COMSTAT, based on the methods 
described in Heydorn et al. study [28] and then presented 
as three-dimensional structures [29]. Briefly, the recon-
structed tagged image format file (.TIFF) images were 
converted from greyscale into a black-and-white picture 
that could be analysed by the COMSTAT program. The 
threshold settings were achieved by comparing the origi-
nal greyscale picture with the black-and-white picture, 
and the best value was chosen to give the most accurate 
conversion of the greyscale to the black-and-white picture. 
This threshold value is fixed and then used for all image 
stacks [30].
2.2.11  In vitro drug release: theoretical perspective
It is worth mentioning that the release mechanism from 
these devices is a complex phenomenon influenced by a 
number of factors. It is believed that methods of encap-
sulation, device dimensions and geometry, the condi-
tions of drug release medium, type of device materials 
and drug–material interactions affect the release mecha-
nism [31]. The assumption taken into consideration here 
is that the drug particles or particles loaded with drugs 
are randomly dispersed throughout the uniform matrix 
with known geometry and have a constant probability of 
finding drug at all positions in the polymer matrix [32]. 
Based on our previous studies, it was shown that release 
behaviour of a clinical active substance from degradable 
material follows the common pattern consisting of three 
stages [33, 34]. However, a number of other studies have 
indicated that the behaviour of drug release from bio-
degradable materials can follow two or four stages [31].
The common three stages of drug release of the GM 
containing polymeric matrix could briefly be elucidated 
as follows:
1. Stage I At time zero, a polymer matrix quickly gets
hydrated with buffer solution; this happens for the
bulk eroding type of matrices. In this stage drugs close 
to the matrix surface or on the surface diffuses into the 
buffer, the phenomenon typically assimilated as “the
initial burst”. Its magnitude depends on the amount
of drugs present adjacent to the matrix and the drug
solubility.
2. Stage II After the initial release, the polymer matrix
starts to degrade producing soluble degradation prod-
ucts such as oligomers, increasing chain mobility and
consequently pores formation on the polymer matrix. 
Degradation starts in the amorphous region of the
polymer matrix leaving behind pores facilitating fluid
transport, essentially for drug release [35]. The drug
release by diffusion through these pores at this stage
seems to be dominating the release mechanisms and
mass transfer process.
3. Stage III Cumulatively, pores grow bigger as they coa-
lesce as the degradation of the polymer matrix pro-
gresses resulting from water or PBS penetration into
the polymer network and hydrolyzing the polymer
into more soluble oligomers. This provides the chan-
nels for the drug diffusion towards the surface of a
polymer matrix that would otherwise be too dense to 
allow their passage [34]. The drug is released progres-
sively until complete polymer degradation, a process
that depends on the polymer degradation behaviour.
For four-stage drug release behaviour, it has been pro-
posed to have a secondary burst before the final stage 
of drug release from the biodegradable matrix. These 
stages were for the pure polymeric matrix, and addi-
tion of the particulate matter as drug carrier introduces 
additional stages to the process. The above stages do 
not take the dissociation of the hydroxyapatite particles 
and related release, which is related to the microsphere-
containing composites, into account.
During the second and third stages, the coralline 
hydroxyapatite particles release the drugs that incorpo-
rated its nano- and mesopores. After the initial dissolution 
of the drugs in the nano- and mesopores, the structure of 
hydroxyapatite or calcium phosphate degrades, and more 
particles are generated and dissolved, hence further drug 
release. This introduces the drugs and the dissolved Ca and 
phosphate ions to the environment. Dissolution and diffu-
sion processes and kinetics at this stage further influence 
the drug release rate.
3  Results and discussions
The confirmation of the physical presence of drug on the 
loaded hydroxyapatite particles was obtained by scanning 
electron microscopy (SEM). FTIR was used to evaluate an 
alteration of drug loaded in a PLA matrix. Figure 1 shows 
images of gentamicin powder (Fig. 1a), showing spherical 
nano- and microparticles; Fig. 1b, c shows the hydroxyapa-
tite particles before and after loaded with gentamicin. The 
loaded particles display smooth surface evidence of the 
drug presence on their surfaces. Since the particles have 
meso- and nanopores, it is believed that the drug pene-
trated into these pores as well. The particles before loading 
reveal rough surfaces with platelet morphology.
Figure 2 shows FTIR shifts of gentamicin in PLA matrix 
consistent with IR shifts of the drug before embedded 
into the matrix. PLA is represented by the following peaks: 
–C=O (1746 cm−1), –C–H (1451–1358 cm−1), –C–O ester
(1180–1043 cm−1) and –C–O stretch (867–751 cm−1). It is
suggested that there is no evidence of chemical interac-
tion between the drug (GM) and the polymer or chloro-
form. The drug is not regenerated or consumed in any
reaction within the polymer matrix. As shown in 2B gen-
tamicin was detected in the polymer matrix with IR shifts
as minor peaks, amide I–II groups, which are N–H, stretch
(1619 and 1523 cm−1). This is in good agreement with the 
literature [36].
Figure 3A shows the SEM images of the uncoated 
Ti6Al4V screw-shaped dental implant and PLA biocom-
posite-coated Ti6Al4V screw-shaped dental implant 
(Fig. 3b) [37, 38]. While the hydroxyapatite microspheres 
are 100 nm, the final coating is around 400 nm thick.
Drug release profiles of gentamicin-loaded PLA films 
and PLAHAp composites are shown in Fig. 4. It is possible 
Fig. 1  a Gentamicin powder (spherical particles), b surface of HAp microspheres before drug loading, c Gentamicin-loaded HAp (coated 
with GM solution)
that the first stage consists only of the surface-bound 
drug release assimilated as the direct dissolution of drug 
particles into water or solution. This process is relatively 
fast from few hours to a week (t = 0–1 week) and known 
as “burst effect”. The second stage includes a number 
of sub-stages dependent on the drug particles and the 
environment and can be best summarized as “progressive 
cumulative dissolution” (PCD) (t = Week 1–5). In this stage, 
the polymer matrix starts to degrade and allows the liquid 
medium to penetrate into the HAp particles where HAp 
surface-bound drug attached to meso- and nanopores 
starts to dissolve and diffuse out. The rate of dissolution 
is slower due to the time required for the drug to diffuse 
through the HAp particles–matrix interface.
In the third or last stage (t = week 5–15) in addition 
to PCD, the particulate matter starts to break down (a 
relatively slow process) while the release rate is further 
reduced, but it includes the polymeric matrix degrada-
tion, HAp particle dissolution and further drug release at 
a steady-state rate.
This is known as the terminal release where degrada-
tion influences the drug release, which may surpass and 
prolong the drug diffusion mechanism. In our previous 
study [35], we showed that the release from these devices 
significantly prevented bacterial growth. The difference in 
Fig. 2  FTIR spectra of drug-loaded PLA confirming non-denaturation of the drug in the PLA matrix, a after loading with Gentamicin, b 
showing the peaks due to gentamicin
Fig. 3  a Uncoated dental implant surface, b PLAHApGm biocomposite thin-film-coated Ti6AL4V screw-shaped dental implant
drug release between PLAGM and PLAHApGM is signifi-
cant and can be assimilated by the fact that drug takes a 
long time to diffuse from HAp particles pores and then 
through PLA–HAP interface into the dissolution media. 
Having HAp particles embedded into the polymer matrix 
shows the potentials in materials combinational approach 
in controlled release of therapeutic agents.
Therefore, the release mechanism is mainly by diffusion 
from the polymer matrix influenced by the rate of larger 
pore formation, which principally is governed by polymer 
degradation rate. Different factors influence the degrada-
tion rate of the polymer matrix including polymer molecu-
lar weight and surface chemistry.
Four biofilm features, surface to bio-volume ratio, 
roughness coefficient, average thickness and biomass, 
were chosen and calculated by COMSTAT to characterize 
biofilm from S. aureus and P. aeruginosa on PLA thin-film 
composites. These variables were used to interpret bio-
logical and physical characteristics of biofilms based on 
previously published work [28]. The overall volume of bio-
film is represented by biomass, while spatial biofilm size is 
represented by an average biofilm thickness. Biofilm het-
erogeneity is assimilated by roughness coefficient, while 
the surface to bio-volume ratio gives us information on 
the size of biofilm that was exposed to the nutrient flow. 
Figure 5 shows the variations of the biomass of S. aureus 
and P. aeruginosa on the surfaces of PLA composites films.
Figure 6 shows the average biofilm thickness on the surfaces 
of thin-film composites. The results are consistent with the bio-
film volume shown in Fig. 5. P. aeruginosa showed characteristics 
that are consistent with biomass and biofilm thickness due to its 
relatively high level of antimicrobial resistance.
4  Conclusions
The bacterial strains used in this study play a signifi-
cant role in the medical context. The activities of these 
organisms have resulted in a growing interest in their 
Fig. 4  Fractional drug release 
from PLAHApGM and PLAGM 
films. Error bars are mean 
standard deviation (SD) of 
three experimental data
Fig. 5  5-day-old static grown biofilm of S. aureus and P. aeruginosa 
on PLA, PLAGM, PLAHAp, and PLAHApGM showing an average of 
biofilm volume (biomass), reveals relative large biomass for P. aer-
uginosa on PLA, PLAHAp, and PLAHAPGM and significant decrease 
in biomass for films loaded with gentamicin (PLAGM and PLA-
HApGM). The displayed error bars are mean standard deviation (SD) 
of triplicate experimental data
physiology and molecular biology performance, espe-
cially in biofilm formations. It appears that biofilm devel-
opment occurs differently on the same surfaces under 
different strains. Reduction in medical infections in 
dental, and orthopaedic implants and neural prosthe-
ses, lies in the ability to develop medical devices with 
modified materials. The release from these devices sug-
gests that they can be used to release the clinical active 
substances in a prolonged period of time and could also 
be used to deliver the drugs in dental and orthopae-
dic implants and CNS and for the prevention of bacte-
rial infections to neural prostheses. These implants can 
be coated by either spray or dip-coating techniques. 
Currently, the PLAHApGM coating has been tested on 
orthopaedic, dental implants and miniature 3D-printed 
devices and the results are promising. The release rate 
and degradation are all tuneable to suit specific appli-
cations. It is envisaged that control of hydroxyapatite 
particle sizes and their chemical composition and pos-
sible liposome coatings of the particles based on our 
previous work could influence the dissolution rates fur-
ther. Further studies are highly needed to widen the cur-
rent understanding of the biofilms and their prevention 
mechanisms in order to achieve the minimum number 
of medical implant and neuroprosthetics-related infec-
tion incidents.
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